Vermillion Q4 Revenues Spike 45 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Thursday that its fourth quarter revenues grew 45 percent year over year on an increase in revenues generated by its OVA1 ovarian cancer test.

For the three months ended Dec. 31, 2013, the Austin, Texas-based company recorded $1.6 million in total revenues, up from $1.1 million in the year-ago period. Product revenues, comprised of OVA1 sales, rose to $1.5 million from $1.0 million, while licensing revenues were flat at $113,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.